Semaglutide

SELECT

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Lincoff AM et al. · The New England journal of medicine · 2023

Population: Adults with overweight or obesity and established cardiovascular disease, without diabetes

A cardiovascular outcomes trial rather than a weight trial: the primary endpoint was a composite of death from cardiovascular causes, non-fatal myocardial infarction and non-fatal stroke.

Route reported

Subcutaneous

Schedule

Once weekly under the trial protocol

Duration

Mean follow-up of approximately 40 months

Treatment arms

Semaglutide 2.4 mg · Placebo

Context: Enrolment required established cardiovascular disease, so the result does not describe a general population.

STEP 1

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding JPH et al. · The New England journal of medicine · 2021

Population: Adults with overweight or obesity, without diabetes

The pivotal obesity trial for once-weekly semaglutide 2.4 mg, with percentage change in body weight over 68 weeks as a coprimary endpoint.

Route reported

Subcutaneous

Schedule

Once weekly under the trial protocol

Duration

68 weeks

Treatment arms

Semaglutide 2.4 mg · Placebo

Context: Both arms received lifestyle intervention, so the result is not attributable to the drug alone. The material studied was the manufacturer's formulation.

Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial

Marx N et al. · Circulation · 2025

The study reportedOral semaglutide reduced major adverse cardiovascular event outcomes independently of concomitant SGLT2i treatment, and this combination appeared to be safe.

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

Kadowaki T et al. · The lancet. Diabetes & endocrinology · 2022

The study reportedAdults from east Asia with obesity, with or without type 2 diabetes, given semaglutide 2·4 mg once a week had superior and clinically meaningful reductions in bodyweight, and greater reductions in abdominal visceral fat area compared with placebo, representing a promising treatment option for weight management in this population.

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Davies M et al. · Lancet (London, England) · 2021

The study reportedIn adults with overweight or obesity, and type 2 diabetes, semaglutide 2·4 mg once a week achieved a superior and clinically meaningful decrease in bodyweight compared with placebo.

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Husain M et al. · The New England journal of medicine · 2019

The study reportedIn this trial involving patients with type 2 diabetes, the cardiovascular risk profile of oral semaglutide was not inferior to that of placebo.

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Pratley RE et al. · The lancet. Diabetes & endocrinology · 2018

The study reportedAt low and high doses, semaglutide was superior to dulaglutide in improving glycaemic control and reducing bodyweight, enabling a significantly greater number of patients with type 2 diabetes to achieve clinically meaningful glycaemic targets and weight loss, with a similar safety profile.

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

Ahrén B et al. · The lancet. Diabetes & endocrinology · 2017

The study reportedOnce-weekly semaglutide was superior to sitagliptin at improving glycaemic control and reducing bodyweight in participants with type 2 diabetes on metformin, thiazolidinediones, or both, and had a similar safety profile to that of other GLP-1 receptor agonists.

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Sorli C et al. · The lancet. Diabetes & endocrinology · 2017

The study reportedSemaglutide significantly improved HbA1c and bodyweight in patients with type 2 diabetes compared with placebo, and showed a similar safety profile to currently available GLP-1 receptor agonists, representing a potential treatment option for such patients.